Afficher la notice abrégée

Long-term results of autologous scaffold-free tissue-engineered vascular graft for hemodialysis access

dc.rights.licenseopenen_US
dc.contributor.authorWYSTRYCHOWSKI, Wojciech
dc.contributor.authorGARRIDO, Sergio A
dc.contributor.authorMARINI, Alicia
dc.contributor.authorDUSSERRE, Nathalie
dc.contributor.authorRADOCHONSKI, Sam
dc.contributor.authorZAGALSKI, Krzysztof
dc.contributor.authorANTONELLI, Jorge
dc.contributor.authorCANALIS, Manuel
dc.contributor.authorSAMMARTINO, Andrea
dc.contributor.authorDAROCHA, Zbigniew
dc.contributor.authorBACZYŃSKI, Ryszard
dc.contributor.authorCIERNIAK, Tomasz
dc.contributor.authorREGELE, Heinz
dc.contributor.authorDE LA FUENTE, Luis M
dc.contributor.authorCIERPKA, Lech
dc.contributor.authorMCALLISTER, Todd N
hal.structure.identifierBioingénierie tissulaire [BIOTIS]
dc.contributor.authorL’HEUREUX, Nicolas
dc.date.accessioned2025-03-19T12:53:17Z
dc.date.available2025-03-19T12:53:17Z
dc.date.issued2022-06-30
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/205562
dc.description.abstractEnBackground: The growing size of the end stage renal disease (ESRD) population highlights the need for effective dialysis access. Exhausted native vascular access options have led to increased use of catheters and prosthetic shunts, which are both associated with high risks of access failure and infection. Emerging alternatives include tissue-engineered vascular grafts (TEVG). Here we present the endpoint results for 10 ESRD patients with the scaffold-free tissue-engineered vascular access produced from sheets of extracellular matrix produced in vitro by human cells in culture. Methods: Grafts were implanted as arteriovenous shunts in 10 ESRD patients with a complex history of access failure. Follow-up included ultrasound control of graft morphology and function, dialysis efficiency, access failure, intervention rate, as well as immunohistochemical analysis of graft structure. Results: One patient died of unrelated causes and three shunts failed to become useable access grafts during the 3-month maturation phase. The 12-month primary and secondary patency for the other six shunts was 86%. Survival of six shunts functioning as the vascular access was 22 ± 12 months with longest primary patency of 38.6 months. The dialysis event rate of 3.34 per patient-year decreased significantly with the use of this TEVG to 0.67. Conclusions: This living autologous tissue-engineered vascular graft seems to be an alternative to synthetic vascular access options, exhibiting advantages of native arteriovenous fistula. © The Author(s) 2022.
dc.language.isoENen_US
dc.title.enLong-term results of autologous scaffold-free tissue-engineered vascular graft for hemodialysis access
dc.typeArticle de revueen_US
dc.identifier.doi10.1177/11297298221095994en_US
dc.subject.halSciences du Vivant [q-bio]en_US
bordeaux.journalJournal of Vascular Accessen_US
bordeaux.page254 – 264en_US
bordeaux.volume25en_US
bordeaux.hal.laboratoriesBioingénierie Tissulaire (BioTis) - U1026en_US
bordeaux.issue1en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionCNRSen_US
bordeaux.institutionINSERMen_US
bordeaux.institutionCHU de Bordeauxen_US
bordeaux.institutionInstitut Bergoniéen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exportfalse
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal%20of%20Vascular%20Access&rft.date=2022-06-30&rft.volume=25&rft.issue=1&rft.spage=254%20%E2%80%93%20264&rft.epage=254%20%E2%80%93%20264&rft.au=WYSTRYCHOWSKI,%20Wojciech&GARRIDO,%20Sergio%20A&MARINI,%20Alicia&DUSSERRE,%20Nathalie&RADOCHONSKI,%20Sam&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée